Personal information

No personal information available

Activities

Collapse all

Works (4)

Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial

American Journal of Hematology
2024-09 | Journal article
DOI: 10.1002/ajh.27410
Contributors: Moshe Mittelman; David H. Henry; John A. Glaspy; Anil Tombak; Rosemary Harrup; Inho Kim; Krzysztof Mądry; Barbara Grabowska; Tyson Lee; Katharina Modelska
Source: check_circle
Crossref

Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies

American Journal of Hematology
2023-05 | Journal article
DOI: 10.1002/ajh.26865
Contributors: John Glaspy; Nashat Y. Gabrail; Patricia Locantore‐Ford; Tyson Lee; Katharina Modelska; Vivek Samal; David H. Henry
Source: check_circle
Crossref

Lenalidomide and the Expanding Toolkit to Manage Kaposi Sarcoma

Clinical Cancer Research
2022-06-13 | Journal article
DOI: 10.1158/1078-0432.CCR-22-0884
Contributors: David H. Henry; Robert G. Maki
Source: check_circle
Crossref

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

American Journal of Hematology
2022-02 | Journal article
DOI: 10.1002/ajh.26397
Contributors: David H. Henry; John Glaspy; Rosemary Harrup; Moshe Mittelman; Amy Zhou; Hetty E. Carraway; Charles Bradley; Gopal Saha; Katharina Modelska; Pamela Bartels et al.
Source: check_circle
Crossref
How many people are using ORCID?